Month: September 2024

New AI-powered feature launches early, positioning RELI Exchange for substantial premium growth and commission revenue boost LAKEWOOD, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: RELI) (“Reliance”, “we” or the “Company”) today announced the official launch of the beta version of its highly anticipated AI-powered Quote & Bind InsurTech solution for commercial policies. Initially scheduled for release in Q4 2024, the new solution has been launched ahead of schedule, giving RELI Exchange agency partners immediate access to this cutting-edge technology. The solution, now live on the RELI Exchange platform, enables agents to generate real-time quotes and bind commercial insurance policies instantly from their dashboard. This advanced system covers a wide range of commercial insurance lines, including...

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Chardan 8th Annual Genetic Medicines Conference in New York City on Tuesday, October 1, 2024, at 1:00 p.m. ET. A live webcast of this presentation will be available on the Investor Relations page of the Wave Life Sciences website at http://ir.wavelifesciences.com. A replay of this presentation will be archived and available on the site for a limited time following the event. About Wave Life SciencesWave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking...

HighlightsShareholders of record on November 06, 2024 to vote at Shareholder meeting to be held on December 09, 2024 Foremost Shareholders as of December 09, 2024, will receive 2 Rio Grande Resources Shares for every 1 Foremost Share, if shareholders vote to approve the Plan of Arrangement The board of directors of Foremost unanimously recommends that Foremost Shareholders vote FOR the resolution to approve the ArrangementVANCOUVER, British Columbia, Sept. 30, 2024 (GLOBE NEWSWIRE) — Foremost Clean Energy Ltd., (NASDAQ: FMST) (CSE: FAT) (“Foremost Clean Energy”, “Foremost” or the “Company”) an emerging North American uranium and lithium exploration company, is pleased to announce that, further to its announcement of July 30, 2024 with respect to the proposed spin-out of the Winston Group of Gold and Silver Properties (the...

NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) — JP 3E Holdings, Inc. (OTC: SPZI), formerly Spooz, Inc., has achieved another major milestone by completing its second shipment of Aluminum Ingot (A7) through its innovative Trade Finance platform in collaboration with Bloxcross. This latest shipment of 1,000 metric tons (MT) follows an initial shipment of 500MT, bringing the total shipped to date to 1,500MT. As global demand for aluminum continues to soar JP 3E is well positioned to capitalize on this growth. This transaction highlights the success of Bloxcross’ newly launched Trade Finance platform, which streamlines global trade transactions, making them faster and more efficient while boosting the likelihood of successful deal closures. JP 3E anticipates many more successful global commodity transactions continuing to drive growth...

RISHON LEZION, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) — B.O.S. Better Online Solutions Ltd. (“BOS” or the “Company”) (NASDAQ: BOSC), an integrator of supply chain technologies, announced today that its Chief Executive Officer, Eyal Cohen, will participate in the upcoming LD Micro Main Event, scheduled for October 28-30, 2024 in Los Angeles, California. The LD Micro Main Event is one of the most influential small-cap and micro-cap investor conferences, bringing together investors, business leaders, and innovators from across various industries. During the event, Eyal Cohen will present to investors and attendees BOS’s business strategy, new developments, growth plans and financial outlook. Eyal Cohen will also engage in one-on-one meetings with current and potential investors, discussing BOS’s vision for the future and the value...

Anchor value-based payor partnership leads to opening of locations in Portland and Salem CERRITOS, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the nation, is proud to announce its expansion into Oregon with the opening of two new specialty cancer clinics. The clinic locations in Portland and Salem will mark TOI’s first capitated partnership in the market, with plans to expand to other markets in the state as additional partnerships develop. Both initial Oregon clinic locations will offer cutting edge cancer care services, offering a vital new option for patients in the Pacific Northwest. “At TOI, we believe that every cancer patient deserves access to the most advanced care in their community,” said Dr. Dan Virnich, Chief Executive Officer...

SAN JOSE, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) — Infinera (NASDAQ: INFN) announced today that its greenhouse gas (GHG) emission reduction targets have been validated by the Science Based Targets initiative (SBTi). This third-party validation reinforces Infinera’s commitment to promoting sustainability in the telecommunications industry through energy-efficient optical networking solution design and environmental, social, and governance (ESG) initiatives. SBTi is a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. SBTi’s Target Validation Team has classified Infinera’s Scope 1 and Scope 2 target ambitions as in line with keeping global warming to 1.5°C in accordance with the Paris Agreement. SBTi validates that Infinera’s 1.5°C-aligned...

CARMEL, Ind., Sept. 30, 2024 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that both the rationale and design of the Phase 2 Avail™ trial of MBX 2109, the Company’s potential long-acting parathyroid hormone (PTH) peptide prodrug, in adults with hypoparathyroidism (HP) were featured in a poster presentation at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting held in Toronto, ON, Canada September 27-30, 2024. “We are pleased to share more information on our ongoing Phase 2 MBX 2109 trial in patients with HP at ASBMR,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences....